Entries of Herrlinger, U. on the publication server
 | Up a level |
Jump to: 2023
Number of items: 1.
2023
Weller, J. 
, Schäfer, N., Schaub, C., Tzaridis, T. , Zeyen, T., Schneider, M. , Potthoff, A. L., Giordano, F. A. , Steinbach, J. P., Zeiner, P. S., Kowalski, T., Sabel, M. , Hau, P., Krex, D., Grauer, O., Goldbrunner, R., Schnell, O., Tabatabai, G. , Ringel, F., Schmidt-Graf, F., Brehmer, S., Tonn, J. C., Bullinger, L. , Vajkoczy, P., Glas, M., Vatter, H., Herrlinger, U. and Seidel, C.
(2023)
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
Journal of Neuro-Oncology 161 (1), pp. 147-153.
Fulltext not available.
, Schäfer, N., Schaub, C., Tzaridis, T. , Zeyen, T., Schneider, M. , Potthoff, A. L., Giordano, F. A. , Steinbach, J. P., Zeiner, P. S., Kowalski, T., Sabel, M. , Hau, P., Krex, D., Grauer, O., Goldbrunner, R., Schnell, O., Tabatabai, G. , Ringel, F., Schmidt-Graf, F., Brehmer, S., Tonn, J. C., Bullinger, L. , Vajkoczy, P., Glas, M., Vatter, H., Herrlinger, U. and Seidel, C.
(2023)
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
Journal of Neuro-Oncology 161 (1), pp. 147-153.
Fulltext not available.